Evaluation of Leukocytes, B and T Lymphocytes, and expression of CD200 and CD23 on B lymphocytes in Patients with Atopic Dermatitis on Dupilumab Therapy—Pilot Study
Abstract Background There are a lot of studies that describe the change in quantity of T cells in patients with atopic dermatitis (AD) compared with healthy subjects. Other components of lymphocytes such as B cells are not examined as well as T cells. Objective We focus on immunophenotyping of B cel...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2023-04-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-023-00918-y |
| _version_ | 1797832216037818368 |
|---|---|
| author | Jarmila Čelakovská Eva Čermáková Petra Boudková Ctirad Andrýs Jan Krejsek |
| author_facet | Jarmila Čelakovská Eva Čermáková Petra Boudková Ctirad Andrýs Jan Krejsek |
| author_sort | Jarmila Čelakovská |
| collection | DOAJ |
| description | Abstract Background There are a lot of studies that describe the change in quantity of T cells in patients with atopic dermatitis (AD) compared with healthy subjects. Other components of lymphocytes such as B cells are not examined as well as T cells. Objective We focus on immunophenotyping of B cells with their subsets (memory, naïve, switched, non-switched) and the expression of CD23 and CD200 markers in patients with AD with and without dupilumab therapy. We also evaluate the count of leukocytes and their subsets, T lymphocytes (CD4+, CD8+), natural killer (NK) cells, and T regulatory cells. Methods A total of 45 patients suffering from AD were examined: 32 patients without dupilumab treatment (10 men, 22 women, average age 35 years), 13 patients with dupilumab treatment (7 men, 6 women, average age 43.4 years), and 30 subjects as a control group (10 men, 20 women, average age 44.7 years). Immunophenotype was examined by flow cytometry in which monoclonal antibodies with fluorescent molecules were used. We compared the absolute and relative count of leukocytes and their subsets, T lymphocytes (CD4+ , CD8+), NK cells, T regulatory cells, absolute and relative count of B lymphocytes (memory, naïve, non-switched, switched, transient), and expression of CD23 and CD200 activation markers on B cells and on their subsets in patients with AD and control group. For statistical analysis we used nonparametric Kruskal–Wallis one-factor analysis of variance with post hoc by Dunn’s test with Bonferroni modification of significance level. Results In patients with AD with and without dupilumab therapy we confirmed the significantly higher count of neutrophils, monocytes, and eosinophils; there was no difference in absolute count of B cells, NK cells and transitional B cells compared with control subjects. We confirmed higher expression of activation marker CD23 on total, memory, naïve, non-switched, and switched B lymphocytes and higher expression of CD200 on total B lymphocytes in both groups of patients with AD compared with controls. In patients without dupilumab therapy we confirmed significantly higher count of relative monocytes, relative eosinophils, and higher expression of CD200 on memory, naïve, and non-switched B lymphocytes compared with controls. In patients with dupilumab therapy we confirmed significantly higher expression of CD200 on switched B lymphocytes, higher count of relative CD4+ T lymphocytes, and lower count of absolute CD8+ T lymphocytes compared with controls. Conclusion This pilot study shows higher expression of CD23 on B lymphocytes and on their subsets in patients with AD with and without dupilumab therapy. The higher expression of CD200 on switched B lymphocytes is confirmed only in patients with AD with dupilumab therapy. |
| first_indexed | 2024-04-09T14:04:14Z |
| format | Article |
| id | doaj.art-4d88e37202b34107a586bedc0b32788a |
| institution | Directory Open Access Journal |
| issn | 2193-8210 2190-9172 |
| language | English |
| last_indexed | 2024-04-09T14:04:14Z |
| publishDate | 2023-04-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Dermatology and Therapy |
| spelling | doaj.art-4d88e37202b34107a586bedc0b32788a2023-05-07T11:06:13ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722023-04-011351171119210.1007/s13555-023-00918-yEvaluation of Leukocytes, B and T Lymphocytes, and expression of CD200 and CD23 on B lymphocytes in Patients with Atopic Dermatitis on Dupilumab Therapy—Pilot StudyJarmila Čelakovská0Eva Čermáková1Petra Boudková2Ctirad Andrýs3Jan Krejsek4Department of Dermatology and Venereology, Faculty Hospital and Medical Faculty of Charles UniversityDepartment of Medical Biophysics, Medical Faculty of Charles UniversityDepartment of Clinical Immunology and Allergy, Faculty Hospital and Medical Faculty of Charles UniversityDepartment of Clinical Immunology and Allergy, Faculty Hospital and Medical Faculty of Charles UniversityDepartment of Clinical Immunology and Allergy, Faculty Hospital and Medical Faculty of Charles UniversityAbstract Background There are a lot of studies that describe the change in quantity of T cells in patients with atopic dermatitis (AD) compared with healthy subjects. Other components of lymphocytes such as B cells are not examined as well as T cells. Objective We focus on immunophenotyping of B cells with their subsets (memory, naïve, switched, non-switched) and the expression of CD23 and CD200 markers in patients with AD with and without dupilumab therapy. We also evaluate the count of leukocytes and their subsets, T lymphocytes (CD4+, CD8+), natural killer (NK) cells, and T regulatory cells. Methods A total of 45 patients suffering from AD were examined: 32 patients without dupilumab treatment (10 men, 22 women, average age 35 years), 13 patients with dupilumab treatment (7 men, 6 women, average age 43.4 years), and 30 subjects as a control group (10 men, 20 women, average age 44.7 years). Immunophenotype was examined by flow cytometry in which monoclonal antibodies with fluorescent molecules were used. We compared the absolute and relative count of leukocytes and their subsets, T lymphocytes (CD4+ , CD8+), NK cells, T regulatory cells, absolute and relative count of B lymphocytes (memory, naïve, non-switched, switched, transient), and expression of CD23 and CD200 activation markers on B cells and on their subsets in patients with AD and control group. For statistical analysis we used nonparametric Kruskal–Wallis one-factor analysis of variance with post hoc by Dunn’s test with Bonferroni modification of significance level. Results In patients with AD with and without dupilumab therapy we confirmed the significantly higher count of neutrophils, monocytes, and eosinophils; there was no difference in absolute count of B cells, NK cells and transitional B cells compared with control subjects. We confirmed higher expression of activation marker CD23 on total, memory, naïve, non-switched, and switched B lymphocytes and higher expression of CD200 on total B lymphocytes in both groups of patients with AD compared with controls. In patients without dupilumab therapy we confirmed significantly higher count of relative monocytes, relative eosinophils, and higher expression of CD200 on memory, naïve, and non-switched B lymphocytes compared with controls. In patients with dupilumab therapy we confirmed significantly higher expression of CD200 on switched B lymphocytes, higher count of relative CD4+ T lymphocytes, and lower count of absolute CD8+ T lymphocytes compared with controls. Conclusion This pilot study shows higher expression of CD23 on B lymphocytes and on their subsets in patients with AD with and without dupilumab therapy. The higher expression of CD200 on switched B lymphocytes is confirmed only in patients with AD with dupilumab therapy.https://doi.org/10.1007/s13555-023-00918-yAtopic dermatitis expression of activation marker CD23CD200 on B cells dupilumab |
| spellingShingle | Jarmila Čelakovská Eva Čermáková Petra Boudková Ctirad Andrýs Jan Krejsek Evaluation of Leukocytes, B and T Lymphocytes, and expression of CD200 and CD23 on B lymphocytes in Patients with Atopic Dermatitis on Dupilumab Therapy—Pilot Study Dermatology and Therapy Atopic dermatitis expression of activation marker CD23 CD200 on B cells dupilumab |
| title | Evaluation of Leukocytes, B and T Lymphocytes, and expression of CD200 and CD23 on B lymphocytes in Patients with Atopic Dermatitis on Dupilumab Therapy—Pilot Study |
| title_full | Evaluation of Leukocytes, B and T Lymphocytes, and expression of CD200 and CD23 on B lymphocytes in Patients with Atopic Dermatitis on Dupilumab Therapy—Pilot Study |
| title_fullStr | Evaluation of Leukocytes, B and T Lymphocytes, and expression of CD200 and CD23 on B lymphocytes in Patients with Atopic Dermatitis on Dupilumab Therapy—Pilot Study |
| title_full_unstemmed | Evaluation of Leukocytes, B and T Lymphocytes, and expression of CD200 and CD23 on B lymphocytes in Patients with Atopic Dermatitis on Dupilumab Therapy—Pilot Study |
| title_short | Evaluation of Leukocytes, B and T Lymphocytes, and expression of CD200 and CD23 on B lymphocytes in Patients with Atopic Dermatitis on Dupilumab Therapy—Pilot Study |
| title_sort | evaluation of leukocytes b and t lymphocytes and expression of cd200 and cd23 on b lymphocytes in patients with atopic dermatitis on dupilumab therapy pilot study |
| topic | Atopic dermatitis expression of activation marker CD23 CD200 on B cells dupilumab |
| url | https://doi.org/10.1007/s13555-023-00918-y |
| work_keys_str_mv | AT jarmilacelakovska evaluationofleukocytesbandtlymphocytesandexpressionofcd200andcd23onblymphocytesinpatientswithatopicdermatitisondupilumabtherapypilotstudy AT evacermakova evaluationofleukocytesbandtlymphocytesandexpressionofcd200andcd23onblymphocytesinpatientswithatopicdermatitisondupilumabtherapypilotstudy AT petraboudkova evaluationofleukocytesbandtlymphocytesandexpressionofcd200andcd23onblymphocytesinpatientswithatopicdermatitisondupilumabtherapypilotstudy AT ctiradandrys evaluationofleukocytesbandtlymphocytesandexpressionofcd200andcd23onblymphocytesinpatientswithatopicdermatitisondupilumabtherapypilotstudy AT jankrejsek evaluationofleukocytesbandtlymphocytesandexpressionofcd200andcd23onblymphocytesinpatientswithatopicdermatitisondupilumabtherapypilotstudy |